vorinostat has been researched along with Biliary Tract Neoplasms in 1 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
Biliary Tract Neoplasms: Tumors or cancer in the BILIARY TRACT including the BILE DUCTS and the GALLBLADDER.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shio, S | 1 |
| Kodama, Y | 1 |
| Ida, H | 1 |
| Shiokawa, M | 1 |
| Kitamura, K | 1 |
| Hatano, E | 1 |
| Uemoto, S | 1 |
| Chiba, T | 1 |
1 other study available for vorinostat and Biliary Tract Neoplasms
| Article | Year |
|---|---|
Loss of RUNX3 expression by histone deacetylation is associated with biliary tract carcinogenesis.
Topics: Acetylation; Biliary Tract Neoplasms; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Chrom | 2011 |